Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

To join this study, your doctor will first need to confirm you have liver cancer (hepatocellular carcinoma) that has returned after you had a liver transplant. The good news is, if you've already had one treatment for your advanced liver cancer like sorafenib or lenvatinib, you might still be able to join. However, if you've already had cabozantinib before, or if your cancer could be cured by surgery or other local treatments, then this study might not be suitable for you.

There are also some general health requirements. You need to be at least 18 years old, and generally feel well enough to carry out most of your daily activities. You also need to have good function of your organs, like your heart, liver, and kidneys. If you have active infections, serious heart problems, or other significant ongoing health issues, you might not be able to take part. Your doctor will carefully check all these details to see if this study is right for you.

If you join this study, it will involve different stages. First, there's a 'screening' period where you'll have tests and checks to make sure the study is safe and suitable for you. This might involve several visits to the clinic.

During the 'study drug period,' you'll take the medicine, cabozantinib, as your study doctor tells you. You'll need to visit the clinic about once a week for check-ups, tests, and to make sure the medicine is working and you're not having any serious side effects. You'll continue taking the medicine until it's no longer helping your cancer or if you experience side effects that become too difficult to manage.

After you stop taking the medicine, you'll have a final visit about a month later. Following this, you'll have follow-up calls or visits about every 8 weeks so the doctors can continue to monitor your health. If you're experiencing side effects, they'll check in with you more often at first, weekly, and then monthly, until those side effects get better or become stable.